Shanghai HeartCare Medical Technology Corp Ltd
HKEX:6609

Watchlist Manager
Shanghai HeartCare Medical Technology Corp Ltd Logo
Shanghai HeartCare Medical Technology Corp Ltd
HKEX:6609
Watchlist
Price: 21.4 HKD 1.66% Market Closed
Market Cap: 831.1m HKD
Have any thoughts about
Shanghai HeartCare Medical Technology Corp Ltd?
Write Note

Shanghai HeartCare Medical Technology Corp Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai HeartCare Medical Technology Corp Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai HeartCare Medical Technology Corp Ltd
HKEX:6609
Income from Continuing Operations
-ÂĄ94m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Income from Continuing Operations
ÂĄ522.1m
CAGR 3-Years
71%
CAGR 5-Years
99%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Income from Continuing Operations
ÂĄ1.7B
CAGR 3-Years
3%
CAGR 5-Years
16%
CAGR 10-Years
19%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Income from Continuing Operations
ÂĄ12.7B
CAGR 3-Years
19%
CAGR 5-Years
25%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Income from Continuing Operations
ÂĄ701.3m
CAGR 3-Years
-13%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Income from Continuing Operations
ÂĄ2B
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai HeartCare Medical Technology Corp Ltd
Glance View

Market Cap
831.1m HKD
Industry
Health Care

Shanghai Heartcare Medical Technology Corp. Ltd. engages in the research, development, manufacture, and sale of neuro-interventional medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-08-20. The firm's product portfolio includes both neuro-interventional and cardiac medical devices, and its main products are CaptorTM thrombectomy device (Captor) and left atrial appendage occluder. The firm's product portfolio extends from the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis to the treatment of hemorrhagic stroke. The firm's other products include the balloon guiding catheter, the ExtraFlex distal access catheter and SupSelek microcatheter. The firm distributes its products within the domestic market.

Intrinsic Value
34.56 HKD
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Shanghai HeartCare Medical Technology Corp Ltd's Income from Continuing Operations?
Income from Continuing Operations
-94m CNY

Based on the financial report for Dec 31, 2023, Shanghai HeartCare Medical Technology Corp Ltd's Income from Continuing Operations amounts to -94m CNY.

What is Shanghai HeartCare Medical Technology Corp Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
24%

Over the last year, the Income from Continuing Operations growth was 53%. The average annual Income from Continuing Operations growth rates for Shanghai HeartCare Medical Technology Corp Ltd have been 24% over the past three years .

Back to Top